Generic Name and Formulations:
Dipyridamole 200mg (extended-release), aspirin 25mg (immediate-release); caps.
Boehringer Ingelheim Pharmaceuticals
Indications for AGGRENOX:
To reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.
Swallow whole. 1 cap twice daily, one in the morning and one in the evening. Alternative regimen in case of intolerable headaches: switch to 1 cap at bedtime and low-dose aspirin in AM; return to usual regimen as soon as possible, usually within 1 week.
NSAID allergy. Patients with the syndrome of asthma, rhinitis, and nasal polyps. Viral infection in children/teens (risk of Reye syndrome).
Not interchangeable with individual components of aspirin and dipyridamole. Increased risk of bleeding, including GI bleed. History of active peptic ulcer, severe hepatic or renal dysfunction; avoid. Coronary artery disease. Pre-existing hypotension. Chronic, heavy alcohol use. Pregnancy (Cat.D); avoid during 3rd trimester and during labor & delivery. Nursing mothers.
Increased risk of bleeding with anticoagulants, antiplatelets, heparin, anagrelide, fibrinolytic therapy, alcohol, chronic NSAID use. Potentiates adenosine, acetazolamide, methotrexate, oral hypoglycemics. May antagonize ACE inhibitors, β-blockers, diuretics, cholinesterase inhibitors, uricosurics. May increase risk of renal dysfunction with NSAIDs. Monitor phenytoin, valproic acid, other anticonvulsants.
Headache, dyspepsia, abdominal pain, nausea, diarrhea; bleeding risk, increased liver enzymes, hepatic failure.
Hepatic. 99% protein bound.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|